February 16, 2009 - University Clinic Heidelberg, Germany reduces treatment times for the TomoTherapy Hi·Art system from between 40 to 75 percent, while at the same time improving plan quality by further reducing radiation dose to normal tissue.
Based on an in-depth planning study, University Clinic Heidelberg researchers anticipate that a reduction in treatment time of between 40 to 75 percent will be possible with next-generation delivery techniques currently in development by TomoTherapy. Detailed findings of the study will be published later this year.
University Clinic Heidelberg installed the Hi·Art treatment system in March 2006. In December 2008, the medical team, led by professor Jürgen Debus, M.D., professor Klaus Herfarth, M.D., and Florian Sterzing, M.D., treated its 500th cancer patient with TomoTherapy’s unique CT platform-based solution for image-guided, intensity-modulated radiation therapy (IG-IMRT).
“TomoTherapy is used in our clinic to treat a wide range of cancer cases. Because of its advanced capabilities over conventional linear accelerators, the system plays an important role for indications where a large volume is to be irradiated and avoidance of critical structures is paramount,” said Dr. Sterzing. “These cases can require longer treatment times to gain optimal results. However, with the advanced TomoTherapy delivery technique, our research indicates that we should be able to treat these most complex cases in as little as 25 percent of the time necessary now. This is with no compromise in the excellent plan quality to which we are accustomed. In fact, we believe treatment quality will be improved.”
Emphasizing that the enhancements will not just benefit cases involving large or complex tumors, Dr. Sterzing added: “Any treatment you do at the moment will likely be faster, and of even higher quality.”

For more information: www.tomotherapy.com and www.klinikum.uni-heidelberg.de/Radioonkologie-und-Strahlentherapie.251…


Related Content

News | Radiation Oncology

July 9, 2024 — Insights from the latest Mordor Intelligence report, “Radiotherapy Market Size & Share Analysis - Growth ...

Time July 09, 2024
arrow
News | Image Guided Radiation Therapy (IGRT)

June 7, 2022 — Two-year results from the Dysphagia-Aspiration Related Structures (DARS) trial, which is funded by Cancer ...

Time June 07, 2022
arrow
News | Image Guided Radiation Therapy (IGRT)

May 19, 2022 — Brainlab announced that clinicians at UZ Brussel are the first to treat patients with the company’s new ...

Time May 19, 2022
arrow
News | Intensity Modulated Radiation Therapy (IMRT)

March 14, 2022 — RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy ...

Time March 14, 2022
arrow
News | Intensity Modulated Radiation Therapy (IMRT)

October 22, 2021 — RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) as a ...

Time October 22, 2021
arrow
News | Radiation Oncology

August 27, 2021 — For decades, the National Comprehensive Cancer Network (NCCN) recommended forgoing post-lumpectomy ...

Time August 27, 2021
arrow
News | Intensity Modulated Radiation Therapy (IMRT)

October 27, 2020 — A preliminary analysis of photon therapy treatment group 1 from the phase II NRG Oncology clinical ...

Time October 27, 2020
arrow
News | Radiation Therapy

June 10, 2020 — A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides ...

Time June 10, 2020
arrow
News | Radiation Therapy

April 16, 2020 — RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy ...

Time April 16, 2020
arrow
News | Image Guided Radiation Therapy (IGRT)

February 11, 2020 — Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive ...

Time February 11, 2020
arrow
Subscribe Now